Thérapies ciblées

Leung, 1989, Vascular endothelial growth factor is a secreted angiogenic mitogen, Science, 246, 1306, 10.1126/science.2479986 Keck, 1989, Vascular permeability factor, an endothelial cell mitogen related to PDGF, Science, 246, 1309, 10.1126/science.2479987 Cross, 2003, VEGF-receptor signal transduction, Trends Biochem Sci, 28, 488, 10.1016/S0968-0004(03)00193-2 Kowanetz, 2006, Vascular endothelial growth factor signaling pathways: therapeutic perspective, Clin Cancer Res, 12, 5018, 10.1158/1078-0432.CCR-06-1520 Ellis, 2008, VEGF-targeted therapy: mechanisms of anti-tumour activity, Nat Rev Cancer, 8, 579, 10.1038/nrc2403 Kaplan, 2005, VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche, Nature, 438, 820, 10.1038/nature04186 Yang, 2005, Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy, Cancer, 103, 1561, 10.1002/cncr.20942 Faivre, 2006, Current development of mTOR inhibitors as anticancer agents, Nat Rev Drug Discov, 5, 671, 10.1038/nrd2062 Sardari Nia, 2007, Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma, Histopathology, 51, 354, 10.1111/j.1365-2559.2007.02800.x Hlatky, 2002, Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us, J Natl Cancer Inst, 94, 883, 10.1093/jnci/94.12.883 Bruns, 2000, Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases, Cancer, 89, 488, 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.0.CO;2-X Rixe, 2007, Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study, Lancet Oncol, 8, 975, 10.1016/S1470-2045(07)70285-1 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 Escudier, 2007, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, Lancet, 370, 2103, 10.1016/S0140-6736(07)61904-7 Motzer, 2008, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet, 372, 449, 10.1016/S0140-6736(08)61039-9 Hudes, 2007, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838 Willett, 2004, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer, Nat Med, 10, 145, 10.1038/nm988 Jain, 2005, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science, 307, 58, 10.1126/science.1104819 Dickson, 2007, Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy, Clin Cancer Res, 13, 3942, 10.1158/1078-0432.CCR-07-0278 Franco, 2006, Targeted antivascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia, Cancer Res, 66, 3639, 10.1158/0008-5472.CAN-05-3295 Mimura, 2007, Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2, Cancer Immunol Immunother, 56, 761, 10.1007/s00262-006-0234-7 Vivanco, 2002, The phosphatidylinositol 3-Kinase AKT pathway in human cancer, Nat Rev Cancer, 2, 489, 10.1038/nrc839 Hankinson, 1998, Circulating concentrations of insulin-like growth factor-I and risk of breast cancer, Lancet, 351, 1393, 10.1016/S0140-6736(97)10384-1 Hu, 1995, Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase, Science, 268, 100, 10.1126/science.7701328 Neshat, 2001, Enhanced sensitivity of PTEN-deficient tumors to inhibition of RAP/Mtor, Proc Natl Acad Sci U S A, 98, 10314, 10.1073/pnas.171076798 Guba, 2002, Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nat Med, 8, 128, 10.1038/nm0202-128